Regulatory
New Congress, New Landscape: What it Means for the Homeopathic Industry
By Pete Evich, AAHP Government Relations Shutdown Impacts FDA The 116th Congress commenced on Jan. 3 amidst a turbulent backdrop of a partial federal government shutdown. On Jan. 25, after a record-breaking 35-day shutdown, President Trump agreed to sign legislation to fund the impacted federal government agencies until Feb. 15. readm more…
Read MoreOutlook 2019: A Letter from the Board
By AAHP Board of Directors 2019 presents a unique crossroad to the homeopathic industry. As consumer demand for our products rises across North America, so does industry growth—and it is poised to continue growing. With this increased visibility comes increased scrutiny from regulatory bodies and potentially unfriendly consumer groups. While readm more…
Read MoreAccelerating into the New Year
By Mark Land, AAHP President As the homeopathic industry continues to grow, AAHP recognizes the need for constant improvement. This year, building on the momentum we gained in 2018, we plan to accelerate our efforts in the areas of advocacy, education, and outreach. All of our efforts aim to readm more…
Read MoreMid-Term Election Results: What the Homeopathic Industry Needs to Know
By Pete Evich, AAHP Government Relations The outcome of the November elections will translate into some significant changes on Capitol Hill over the next two years. In contests for the House of Representatives, a “blue wave” came ashore that will give the Democrats a solid governing majority in the lower readm more…
Read More2018: A Fast-Paced Year of Advocacy and Education
By AAHP Board of Directors It’s been nearly a year since the U.S. Food and Drug Administration (FDA) published a draft guidance document that would revoke clearly detailed parameters for manufacturing and distributing homeopathic products. The agency proposed a vague, risk-based approach that could hinder, rather than help us produce readm more…
Read MoreA Brief Regulatory History of Process Validation
By Mark Land, AAHP President Finished product testing is probabilistic and not dispositive of process control; that is why we need process validation. While preparing this article I came across several histories of process validation. One that caught my attention was a book chapter written by Bernard Loftus, formerly readm more…
Read MorePrepare for Recalls: 5 Crucial Steps
By Ryan Gooley, Recall Consultant, Stericycle Recalls impact thousands of companies every year, and they represent serious risk for the brands impacted. Homeopathic recalls, especially those involving products meant for children or the elderly, can cause widespread media coverage and consumer panic, potentially flooding call center phone lines and readm more…
Read MoreCrystal Ball: 2018 Federal Election
By Pete Evich, AAHP government relations “It’s tough to make predictions, especially about the future.” ― Yogi Berra With the mid-term federal elections almost five months down the road, it’s high-season for those of us in the business of Congress-watching to prognosticate what is likely to transpire this November. Five readm more…
Read MoreAAHP Rouses 38,000 Letters to Capitol Hill and Garners Congressional Support
As the result of the AAHP’s first grassroots effort, 38,000 letters from consumers and health care providers poured into offices of U.S. senators and representatives this spring. The letter-writing campaign urged Congressional leaders to ask the U.S. Food and Drug Administration (FDA) to incorporate key elements of the 1988 guidance regulating homeopathic readm more…
Read MoreHow Much Can Machine Learning Help Us?
By Mark Land, AAHP President June 4, 2018 FDA docket 2017-D-6580 for comments on the draft guidance for FDA staff and industry entitled “Drug Products Labeled as Homeopathic” closed on Monday, May 21 after a 60-day extension. There were 4,792 comments submitted to the docket. That was about half the readm more…
Read More